) signaling. 1 Volatile anesthetics (VAs) have been shown to alter Ca 2+ entry through voltage-dependent calcium channels [2] [3] [4] [5] [6] and to decrease neurotransmitter release. [7] [8] [9] [10] Calcium ions are important for both excitatory and inhibitory neurotransmission. Because neurotransmitter release depends on the third or fourth power of cytoplasmic Ca 2+ concentration, a small effect on Ca 2+ entry via the voltage-dependent calcium channels could result in a large effect on neurotransmitter release. 11, 12 Therefore, VA-induced effects, such as anesthesia, analgesia, and immobility, may involve VA actions on neuronal Ca 2+ regulation. The spinal cord is the major site at which VAs act to induce immobility as measured by minimum alveolar concentration (MAC). [13] [14] [15] [16] Although isoflurane has little effect in the peri-MAC range on spinal cord dorsal horn neurons, it appears that locomotor networks in the ventral horn of the spinal cord are the predominant site of VA-induced immobility. 15, [17] [18] [19] Dorsal root ganglion neurons (DRGNs) have their terminals within the spinal cord and some synapse with spinal cord motor neurons (SCMN). 14, 16, 17 Because it has been established that anesthetic-induced immobility occurs primarily through an action on the spinal cord, 14, 16, 20 we examined the effect of isoflurane and the nonimmobilizers, F6 (1,2-dichlorohexafluorocyclobutane) and F8 (2,3-dichlorooctafluorobutane), on adult rat DRGN and on SCMN. F6 and F8 are compounds that are predicted by the Meyer-Overton rule, on the basis of their oil solubility, to be anesthetics, 21 but unlike isoflurane, they do not inhibit movement in response to a noxious stimulus. We focused our attention on 2 of the high-voltage activated subtypes of the voltage-dependent calcium channels, Ca V 1 (L-type) and Ca V 2 (N-type). These channels are involved in regulating neuronal excitability and neurotransmitter release. 22 We postulated that if F6 and/or F8 inhibited Ca V 1 and/or Ca V 2 calcium channels in SCMN and/or DRGN, such channels would not be relevant mediators for isoflurane-induced immobility.
METHODS Cell Culture and Solutions
Primary cultures of adult DRGN and adult SCMN were prepared using Adult Sprague-Dawley rats (70-100 days) after the guidelines approved by the New York University Langone Medical Center Institutional Animal Care and Use Committee. Primary cultures of adult rat DRGN and SCMN were prepared and maintained as previously described. 23, 24 DRGN were studied within 48 to 72 hours; SCMN were studied after 2 to 6 weeks. SCMN were identified by their BACKGROUND: Volatile anesthetics decrease Ca 2+ entry through voltage-dependent Ca 2+ channels. Ca 2+ influences neurotransmitter release and neuronal excitability. Because volatile anesthetics act specifically on the spinal cord to produce immobility, we examined the effect of isoflurane and the nonimmobilizers F6 (1, 2-dichlorohexafluorocyclobutane) and F8 (2, 3-dichlorooctafluorobutane) on Ca V 1 and Ca V 2 Ca 2+ channels in spinal cord motor neurons and dorsal root ganglion neurons. METHODS: Using patch clamping, we compared the effects of isoflurane with those of F6 and F8 on Ca V 1 and Ca V 2 channels in isolated, cultured adult rat spinal cord motor neurons and on Ca V 1 and Ca V 2 channels in adult rat dorsal root ganglion sensory neurons. RESULTS: In spinal cord motor neurons, isoflurane, but not F6 or F8, inhibited currents through Ca V 1 channels. Isoflurane and at least one of the nonimmobilizers inhibited currents through Ca V 1 and Ca V 2 channels in dorsal root ganglion neurons and Ca V 2 in spinal cord motor neurons. CONCLUSIONS: The findings that isoflurane, but not nonimmobilizers, inhibited Ca V 1 Ca 2+ channels in spinal cord motor neurons are consistent with the notion that spinal cord motor neurons might mediate isoflurane-induced immobility. Additional studies are required to examine whether inhibition of Ca V 1 calcium currents in spinal cord motor neurons is sufficient or whether actions on other channels/proteins contribute to isoflurane-induced immobility. Isoflurane, but Not the Nonimmobilizers F6 and F8, Inhibits Rat Spinal Cord Motor Neuron Ca V 1 Calcium Currents Esperanza Recio-Pinto, PhD, Jose V. Montoya-Gacharna, MD, Fang Xu, PhD, and Thomas J. J. Blanck, MD, PhD morphology. One rat was used for each cell culture preparation. The data shown in this study came from 18 cell culture preparations: 10 DRGN cell preparations, 6 to examine Ca V 1 channels and 4 to examine Ca V 2 channels; 8 SCMN cell preparations, 3 to examine Ca V 1 channels and 5 to examine Ca V 2 channels. Sufficient cell preparations with response to electrical stimulation, low noise upon recording, and demonstrating reversibility to drug effect were made such that n, the number of cells studied from independent preparations, was ≥3.
Ca V 2 and Ca V 1 Calcium Channel Recordings Total whole-cell Ca V 2 calcium currents were recorded in adult rat SCMN and adult rat DRGN. The pipette solution contained (in mM) 85 CsCl, 10 TEA-Cl (potassium channel blocker), 10 EGTA, 2 MgCl 2 , 10 Hepes, 4 CaCl 2 , and 2 Na 2 ATP at pH 7.4 with CsOH, and the bath solution contained (in mM) 110 NaCl, 10 BaCl 2 , 2 MgCl 2 , 10 glucose, 10 Hepes, pH 7.4, and (in μM) 100 picrotoxin (γ-aminobutyric acid [GABA] receptor antagonist), 50 bicuculline (GABA receptor antagonist), 10 nitrendipine (Ca V 1 channel blocker), and 1 tetrodotoxin (TTX, voltage-dependent sodium channel blocker) (all from Sigma-Aldrich Corp., St. Louis, MO). Recordings were done initially with bath solution to assure that the level of Ca V 2 currents was stable. Cells were perfused continuously while recording, first with bath solution followed by drug, either isoflurane or F6 or F8, and then with bath solution alone. For SCMN, current-voltage relationships were obtained using a series of depolarizing pulses (95-millisecond duration) from −50 mV to +30 mV in steps of 10 mV from a holding potential of −80 mV (20 milliseconds), with 2-second intervals when the potential was held at −60 mV. For DRGN, the duration of the pulse was 40 milliseconds, and the pulses were from −50 to +50 mV, the holding potential was −90 mV (15 milliseconds), and the interval was 4 seconds when the potential was held at −70 mV. Currents were filtered at 2 kHz and digitally sampled at every 5 to 12 microseconds. The membrane capacitance and series resistance were compensated by approximately 80%. Linear leakage currents and residual capacitance were digitally subtracted online with P/4 routines. The current-voltage curves were constructed by measuring the peak current level at each membrane potential. The time-averaged currents at +10 mV were measured.
Because Ca V 1 currents display strong rundown under the whole-cell configuration, single Ca V 1 channel currents were measured using the cell-attached configuration. The pipette solution contained (in mM): 15 BaCl 2 , 110 sucrose, 10 TEA-Cl, 2 EGTA, 2 Hepes, and (in μM): 100 picrotoxinin, 50 bicuculline, 0.9 ω-Conotoxin GVIA (Ca V 2 blocker; Tocris Bioscience, Bristol, UK), 0.1 ω-agatoxin IVA (P-type calcium channel blocker; Tocris Bioscience), 1 TTX, and 2 (S)-(-)-BayK8644 at pH 7.4. The bath solution contained (in mM) 120 K-gluconate, 25 KCl, 2 MgCl 2 , 0.5 CaCl 2 , 2 EGTA, 2 Hepes, and (in μM): 100 picrotoxin, 50 bicuculline, and 1 M TTX, and 2 (S)-(-)BayK8644 at pH 7.4. Current-voltage relationships were done to confirm the nature of the currents. Consecutive pulses of 10 mV increments from −80 to +40 mV were applied from a holding potential of −90 mV (20 milliseconds). For SCMN, the pulse duration was 250 milliseconds and the interval was 2 seconds. For DRGN, the pulse duration was 150 milliseconds and the interval was 4 seconds. In both cases during the interval, the potential was held at −60 mV. For SCMN, 60 to 80 traces and for DRGN 36 traces at 0 mV were used to measure the timeaveraged current before, during, and after drug exposure. Currents were filtered at 1 to 2 kHz and digitally sampled at every 5 to 12 microseconds. The background conductance and capacitance transients were subtracted using a fit to a trace without single channel current events.
A 2-electrode voltage clamp was used (Dagan 3900; Dagan Corporation, Minneapolis, MN; or Axopatch 200B, Axon Instruments, Foster City, CA; Molecular Devices, LLC, Sunnyvale, CA). Output from the voltage clamp amplifier was sent to a microcomputer using a data acquisition interface (Labmaster; Axon Instruments). Pipette resistances were 1.3 to 3 MΩ. Experiments were conducted at room temperature.
Preparation of Isoflurane and Nonimmobilizers
Saturated isoflurane (Forane®, Baxter, IL) solutions (14.6 mM) were prepared in the respective bath solutions. The solutions were prepared in advance in a Teflon-sealed glass container (Sigma-Aldrich Corp., St. Louis, MO) and diluted to the final concentrations used in each experiment immediately before use as previously described. 25 Saturated solutions of the nonimmobilizers F6 (Interchim, Montuçlon, France) and F8 (Interchim; SynQuest Laboratories, Inc., Alachua, FL) were prepared according to the method by Cardoso et al. 26 The saturated solutions of F6 and F8 were prepared the day before the experiments. Saturated F6 (225 μM) and F8 (35 μM) solutions were prepared by adding 200 μL of the nonimmobilizers in 20 mL buffer or 85 μL of the nonimmobilizers in 8.5 mL buffer in Teflon-sealed glass container. The solutions were mixed overnight at room temperature and protected from light. Before removing the appropriate volume of saturated solution, the solutions were left to rest for at least 3 hours. Stock solutions were used only once. Final concentrations were obtained by adding the appropriate volume (collected with a small gas-tight syringe, avoiding the bottom of the bottle) of the saturated solution into a large gas-tight syringe containing bath solution.
The large gas-tight syringe was open only when the drugs (isoflurane, F6 or F8) were being perfused. These drugs were directly applied on the cells through a puffer located directly on top of the cells (perfusion manifold MMF; Scientifica, East Sussex, United Kingdom). Teflon tubing was used between all connections. Finally, measurements were made during continuous perfusion (puffer rate = 0.25 mL/min) with either bath solution alone or bath solution containing isoflurane, F6, or F8.
Data Analysis
Electrophysiology Recordings Data were acquired and analyzed using Pclamp8-10 (Axon Instruments); figures were done using Clampfit (Axon Instruments) and Prism 5.04 (GraphPad Software Inc., San Diego, CA) software. 
Statistical Analysis

RESULTS
In SCMN, Nonimmobilizers Inhibit Ca V 2 (N-Type) but Not Ca V 1 (L-Type) Currents
The effect of isoflurane at 0.6 mM (approximately 2 MAC) and of F8 and F6 at a concentration equivalent to approximately 2 MAC eq (equivalent MAC) (17.6 μM of F8, 38 μM of F6) on Ca V 2 currents in SCMN was compared. Current traces at +10 mV and their corresponding current-voltage relationships for cells before, during drug exposure (isoflurane, F8 or F6). and after drug removal (Fig. 1, A-C) are shown. The current-voltage relationships confirm that the currents were Ca V 2 currents, since they start activating at approximately −30 mV, and their reversal potential was above +40 mV. F6 had the strongest inhibitory effect, followed by F8 and isoflurane (Fig. 1, A-C) . Figure 2 shows the mean of the normalized time-averaged Ca V 2 current values at +10 mV for control and cells exposed to isoflurane and the nonimmobilizers. The magnitude of the time-averaged current for cells treated with drug was normalized for each cell to that measured during the initial perfusion with control solution and then averaged. Isoflurane at 0.6 mM did not significantly inhibit Ca V 2 currents, P = 0.4963 (6 comparisons), while F8 and F6 did, P < 0.0001, and their inhibition was reversible (Fig. 2) .
The effects of isoflurane at 0.3 mM (approximately 1 MAC) with those of F8 (8.8 μM approximately 1 MAC eq ) and F6 (35.6 μM approximately 2 MAC eq ) on Ca V 1 singlechannel currents in SCMN were compared. Figure 3 shows single-channel current traces at various holding potentials and the corresponding single-channel current-voltage relationship that gave a single-channel conductance of approximately 21pS, a property consistent with Ca V 1 single-channel currents. Figure 3B demonstrates single-channel currents 2+ currents in rat spinal cord motor neuron. Normalized time-averaged currents at +10 mV, before (W), during drug exposure (D), and after washing out (W1, W2, and W3) the drug. One-way analysis of variance (P < 0.0001). Bonferroni multiple comparison test (denominator = 6): ^P < 0.0001 between each group and the corresponding control group (n = the number of cells); control n = 13, except W3 n = 9; isoflurane (0.6 mM, approximately 2 minimum alveolar concentration [MAC]) n = 6; F8 (17.6 μM, approximately 2 MAC eq ) n = 6, except W3 n = 3; F6 (35.6 μM, approximately 2 MAC eq ) n = 3, except W2 and W3 n = 1.
before, during, and after exposure to 0.3 mM, approximately 1 MAC, isoflurane. Ca V 1 currents were statistically significantly inhibited by 0.3 mM ( approximately 1 MAC) isoflurane, P = 0.0002 (Fig. 4) , whereas F6, P = 0.9240, and F8, P = 0.3958, at 1 and 2 MAC eq , respectively, had no significant effects (Fig. 4) .
In DRGN Nonimmobilizers Inhibit Ca V 2 (N-Type) and Ca V 1 (L-Type) Calcium Currents Ca V 2 current traces in DRGN were measured at +10 mV, and their corresponding current-voltage relationships for a control cell (Fig. 5A ) and for cells before, during drug exposure (isoflurane or F6), and after drug removal (Fig. 5, B and C) are shown. F6, P < 0.0001, significantly inhibited Ca V 2 currents in DRGN (Fig. 6) , whereas the effect of isoflurane was not consistent, P = 0.037.
In DRGN, we found that isoflurane at approximately 2 MAC (0.6 mM), P = 0.0081, and F6 at approximately 2 MAC eq (35.6 μM), P = 0.0117, but not F8 (17.6 μM), P = 0.3326, significantly inhibited Ca V 1 currents (Fig. 7) . Although the sample size was small, Lilliefors and Shapiro Wilk tests of normality and the Levene test for equal variance of the residuals of the analysis of variance for drug administration and drug administration plus the wash period, respectively, demonstrated normal distributions and equal variances as indicated in the legend of Figure 7 . Because F6 had an inhibitory effect on Ca V 2 and Ca V 1 currents in DRGN, these channels in DRGN are unlikely to be involved in anestheticinduced immobility.
DISCUSSION
SCMN and DRGN were exposed to the nonimmobilizers, F6 and F8, to determine whether Ca V 1 and/or Ca V 2 channels in these neurons might be involved in isoflurane-induced immobility. Ca V 1 channels in SCMN were strongly inhibited at a clinically relevant isoflurane concentration (80% inhibition at 0.3 mM isoflurane approximately 1 MAC) but were not inhibited by F6 or F8 at their 1 or 2 MAC eq , suggesting that SCMN Ca V 1 channels might contribute to isofluraneinduced immobility. However, SCMN Ca V 2 channels were strongly inhibited by F6 and F8 but not by isoflurane (at 2 MAC), suggesting that Ca V 2 channels do not contribute to isoflurane-induced immobility. Furthermore, Ca V 1 and Ca V 2 Ca 2+ channels in rat DRGN were inhibited by F6, suggesting that Ca V 1 and Ca V 2 channels in DRGN do not contribute to isoflurane-induced immobility.
It is well known that Ca V 2 and Ca V 1 calcium channel functions are highly regulated by post-translational modifications (e.g., phosphorylation), as well as by interactions with other cellular proteins, for example, G-proteins; hence, the different responses of a given voltage-dependent www.anesthesia-analgesia.org aNesthesia & aNalgesia calcium channel in SCMN and DRGN could reflect differences not only in their structure but also in modulation by other cellular processes. 5, 27 Regardless of the possible underlying structural or regulatory mechanisms that lead to the different responses to isoflurane and nonimmobilizers for a given channel type in different neuronal cells, our results suggest that calcium signaling, and specifically Ca V 1 calcium channels in SCMN, may be involved in the mechanism of isoflurane-induced immobility.
AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid), NMDA (N-methyl-D-aspartate), glycine, and GABA A receptors are reportedly involved in the overall anesthetic effect, 28, 29 but other receptors and channels may also be relevant. It has been shown that enflurane at 1 MAC depressed synaptic currents in SCMN. 30 A paradigm involving multiple effects of VAs on several ligands and channels has been described that could explain how different ligand and receptors, including voltage-dependent calcium channels, may participate in isoflurane-induced immobility. 31 Our data support Ca V 1 channels in SCMN as one of several targets involved in VA-induced immobility. It is not yet clear how Ca V 1 channels are modulated by VAs, which can act directly on the Ca V 1 channel or indirectly through secondary effectors. It is known that isoflurane can act on the channel by increasing current inactivation and prolonging recovery time after inactivation; for example, halothane inhibits Ca V 1 calcium channels in SH-SY5Y cells through stabilization of nonconducting or inactivated states. 4 We also have shown that activation of G-proteins reduces isoflurane inhibition of Ca V 2 calcium currents in SH-SY5Y cells 5 and in DRGN (unpublished data).
Inhibition of Ca V 1 calcium channels by VAs has been demonstrated. Recombinant cardiac Ca V 1 calcium channels are inhibited by halothane.
2 Ca V 1 calcium channels are involved in neurotransmission, gene expression, and regulating neuronal excitability. 32, 33 Ca V 1 calcium currents mediate rhythmic activity induced by a cholinergic antagonist in motor neurons, suggesting that the entry of calcium through Ca V 1 calcium channels is a significant pathway involved in agonist-modulated locomotor activity. 34 Ca V 1 calcium channels also contribute to NMDA-induced intrinsic oscillations in mature turtle SCMNs. 35 There are also studies showing the effects of VAs on calcium regulation and specifically on voltage-dependent calcium channels. 36 Our results direct attention to Ca V 1 channels in SCMN as a relevant target of VA-induced immobility. The action of the nonimmobilizer F6 on rat DRGN, but not rat SCMN Ca V 1 calcium channels, suggests that these channels in DRGN are not a prominent site of isoflurane-induced immobility. 15, 19 Furthermore, the inhibition by isoflurane of Ca V 1 channels in rat SCMN, but not the nonimmobilizers, supports the work of others describing anesthetic-induced immobility as an effect mediated through the ventral spinal cord. [17] [18] [19] Using the lamprey spinal cord preparation, Jinks et al. 37 concluded that ventral SCMN involved in central pattern locomotor activity were an important site of isofluraneinduced immobility. They subsequently used electrical microstimulation of the mesencephalic locomotor region in decerebrated rats and determined that VAs produce "immobility mainly by action on ventral spinal cord locomotor networks." 15 However, motor neurons themselves have been shown to express persistent oscillatory activity sensitive to Ca V 1 and Ca V 2 Ca 2+ channels and are potentially related to locomotor networks. 34, 35, [38] [39] [40] [41] SCMN express Ca V 1.2,3(L-), Ca V 2.1(N-), Ca V 2.2(P/Q), Ca V 2.3(R), and Ca V 3(T-)type channels, but mainly Ca V 1.2,.3(L-) and Ca V 2.1(N-)type. 42 Both Ca V 1.2 and Ca V 1.3 L-type channels are found in the CNS, and Ca V 1.3 (α 1D ) channels are involved in persistent inward currents, which give SCMN the property of bistability and sustained activation. 39, 41, 43 On the basis of electromyographic studies in the rat, King and Rampil 17 suggested that isoflurane can depress SCMN. They stimulated the tibial nerve of rats and measured the amplitude of the orthodromic (M-wave) and antidromic (F-wave) electromyogram and showed that only the F-wave was inhibited by isoflurane. 17, 18 The F-wave results from the antidromic transmission back to the motor neuron followed by orthodromic transmission from the motor neuron. The Ca V 1 calcium channel is found predominantly in the soma but also in the proximal dendrites of rat SCMN. 44, 45 The action of isoflurane to inhibit calcium movement through the Ca V 1 channel could result in a higher threshold for activating an action potential, resulting in inhibition of neurotransmission. The Ca V 1 channel in the motor neuron has approximately a 75% homogeneity with the Ca V 1 channel in skeletal muscle; yet, as shown in the studies of Rampil, although the F-wave is markedly depressed by isoflurane, the M-wave, representing direct stimulation of the motor endplate, was unaffected by isoflurane. That result suggests that the Ca V 1 channel of the motor neuron and skeletal muscle is sufficiently different that, at the clinically relevant concentrations studied, isoflurane had little effect on the skeletal muscle Ca V 1 calcium channel, despite inhibiting calcium movement through Ca V 1 channels in the SCMN.
Although we have presented evidence that Ca V1 channels in SCMN are a likely target for isoflurane-induced immobility, several limitations must be considered. Our studies were performed in vitro on cultured DRGN and SCMN. Although the identified channels demonstrated characteristics of Ca V 1 and Ca V 2 channels, we cannot rule out the possibility that the isolation process might have altered the channels' response to isoflurane and nonimmobilizers. A further limitation is that the concentrations of isoflurane and F6 and F8 in the solutions bathing the SCMN and DRGN were not measured. However, recordings were performed while the chamber was continuously perfused; moreover, the observed inhibitory effects of F6 and F8, on Ca V 2 channels in SCMN, and Ca V 1 and Ca V 2 channels in DRGN support our methodology and suggest that F6 and F8 were present in the chamber solutions used to examine Ca V 1 channels, despite there being no effect on these channels. Finally, we studied only one VA, isoflurane. Is it unique in its target or do other VAs also induce immobility by targeting the SCMN Ca V 1 channels? There is supporting evidence in other cell types, including primary cultures and expression systems, that some of these VAs can alter Ca V 1 function; however, none of them include Ca V 1 channels from SCMN. Whether Ca V 1 in SCMN are also targeted by other VAs, such as halothane, enflurane, desflurane and sevoflurane, remains to be determined.
The physiologic implication of our findings is related to the fact that calcium contributes to the regulation of neuronal excitability through its actions on many sites within a cell. 46, 47 Activation of Ca V 1 calcium channels leads to increased excitability of neurons, whereas inhibition of Ca V 1 channels can lead to decreased excitability. VAs, including isoflurane, have multiple effects on Ca 2+ homeostasis in neuronal cells. The proposed isoflurane-induced decreased excitability of motor neurons can be related not only to Ca V 1 channel inhibition but might also involve modification of Na + channel conductance and other ion channel conductances involved in intracellular Ca 2+ regulation. In summary, we found that Ca V 1 calcium channels in SCMN could contribute to isoflurane-mediated immobility. Additional studies are required to examine whether inhibition of Ca V 1 Figure 7 . Summary data of F6 inhibition of Ca V 1 currents in dorsal root ganglion neuron. Normalized time-averaged current traces at 0 mV, before (W), during drug exposure (D), and after washing out the drug (W1). Control n = 4 (black), F8 n = 3 (green, 17.6 μM, approximately 2 MAC eq ), and F6 n = 7 (blue, 35.6 μM, approximately 2 MAC). One-way analysis of variance (P = 0.0003) considering exposure to control and F6, and F8. Bonferroni multiple comparison test, denominator = 3: #P = 0.0117 between F6 and control. The Levene test yields P = 0.4500 for drug administration, and P = 0.1049 when the wash periods are included in the analysis, indicating equivalence of variance among groups. The Lilliefors test for normality yields P > 0.1000 for drug administration and P > 0.1000 when wash periods are included. The Shapiro-Wilk test for normality yields P = 0.9765 for drug administration and P = 0.7215 when wash periods are included. Both tests demonstrate normal distributions of the residuals of the analysis of variance. MAC = minimum alveolar concentration.
